Volume 28, Issue 1 - Careers in medical writing

Regulatory Matters

Author: Jennifer Clemens

Abstract

References

1. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the Investigation of Bioequivalence. January 20, 2010 [cited 2018 Sep 10]. Available from: https://www.ema. europa. eu/documents/ scientific-guideline/guideline-investigationbioequivalence- rev1_en.pdf.
2. Cardot J-M, Garcia-Arieta A, Paixao P, Tasevska I, Davit B. Implementing the additional strength biowaiver for generics: EMA recommended approaches and challenges for a US-FDA submission. Eur J Pharm Sci. 2018;111: 399–408.
3. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). ICH Guideline M9 on biopharmaceutics classification system based biowaivers: Step 2b. July 25, 2018 [cited 2018 Sep 10]. Available from: https://www.ema.europa.eu/documents/ scientific-guideline/ich-m9- biopharmaceutics-classification-systembased- biowaivers-step-2b-first-version_ en.pdf.
4. Davit BM, Kanfer I, Tsang YC, Cardot J-M. BCS Biowaivers: Similarities and differences among EMA, FDA, and WHO requirements. The AAPS Journal 2016;18(3): 612–8 [cited 2018 Sep 10]. Available from: https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC5256598/pdf/12248_2016_ Article_9877.pdf.
5. Chen M-L, Blume H, Beuerle G, Davit B, Mehta M, Potthast H, et al. The Global Bioequivalence Harmonisation Initiative: summary report for EUFEPS international conference. Eur J Pharm Sci. 2018;111: 153–7.
6. Drug Delivery Foundation. Provisional BCS Classification. (Database on webpage.) Available from: http://www.ddfint.net/search.cfm.